La Trobe
1/1
2 files

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways

journal contribution
posted on 2021-08-04, 07:27 authored by David GreeningDavid Greening, Sze LeeSze Lee, H Ji, Richard SimpsonRichard Simpson, Angela RigopoulosAngela Rigopoulos, C Murone, C Fang, Sylvia GongSylvia Gong, G O'Keefe, Andrew ScottAndrew Scott
Angiogenesis and epidermal growth factor receptor (EGFR) inhibition has been shown to have anti-tumour efficacy, and enhance the therapeutic effects of cytotoxic chemotherapy in metastatic colorectal cancer. The interplay of signalling alterations and changes in metabolism and hypoxia in tumours following anti-VEGF and anti-EGFR treatment is not well understood. We aimed to explore the pharmacodynamics of cetuximab and bevacizumab treatment in human colon carcinoma tumour cells in vitro and xenograft models through proteomic profiling, molecular imaging of metabolism and hypoxia, and evaluation of therapy-induced changes in tumour cells and the tumour microenvironment. Both cetuximab and bevacizumab inhibited tumour growth in vivo, and this effect was associated with selectively perturbed glucose metabolism and reduced hypoxic volumes based on PET/MRI imaging. Global proteomic profiling of xenograft tumours (in presence of cetuximab, bevacizumab, and combination treatments) revealed alterations in proteins involved in glucose, lipid and fatty acid metabolism (e.g., GPD2, ATP5B, STAT3, FASN), as well as hypoxic regulators and vasculogenesis (e.g., ATP5B, THBS1, HSPG2). These findings correlated with western immunoblotting (xenograft lysates) and histological examination by immunohistochemistry. These results define important mechanistic insight into the dynamic changes in metabolic and hypoxic response pathways in colorectal tumours following treatment with cetuximab and bevacizumab, and highlight the ability of these therapies to selectively impact on tumour cells and extracellular microenvironment.

Funding

The authors were supported, in part, by the National Health and Medical Research Council (NHMRC) of Australia project grants 1087850 (A.M.S), NHMRC Program Grant 487922 (A.M.S, R.J.S), and a La Trobe University Leadership RFA Grant (D.W.G). This work was also supported by Operational Infrastructure Support Program funding provided by the Victorian Government.

History

Publication Date

2015-10-26

Journal

Oncotarget

Volume

6

Issue

35

Pagination

38166 - 38180

Publisher

Impact Journals

ISSN

1949-2553

Rights Statement

© 2015 Impact Journals, LLC Licensed under a Creative Commons Attribution 4.0 License.

Usage metrics

    Journal Articles

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC